Filtered By:
Cancer: Melanoma
Infectious Disease: Pandemics
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Use of Iontophoresis Technology for Transdermal Delivery of a Minimal mRNA Vaccine as a Potential Melanoma Therapeutic
Biol Pharm Bull. 2023;46(2):301-308. doi: 10.1248/bpb.b22-00746.ABSTRACTmRNA vaccines have attracted considerable attention as a result of the 2019 coronavirus pandemic; however, challenges remain regarding use of mRNA vaccines, including insufficient delivery owing to the high molecular weights and high negative charges associated with mRNA. These characteristics of mRNA vaccines impair intracellular uptake and subsequent protein translation. In the current study, we prepared a minimal mRNA vaccine encoding a tumor associated antigen human gp10025-33 peptide (KVPRNQDWL), as a potential treatment for melanoma. Minimal mRNA...
Source: Biological and Pharmaceutical Bulletin - February 1, 2023 Category: Drugs & Pharmacology Authors: Rabab A Husseini Naoko Abe Tomoaki Hara Hiroshi Abe Kentaro Kogure Source Type: research
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
